Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010851 | 0.84 | KMT2A (0.67) | KMT2AATMMC4RMAPTPOLB | |
| SCHEMBL15079855 | 0.79 | CYP4F2 (0.49) | KMT2ATAAR1L3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL1010079 | 0.79 | KMT2A (0.54) | KMT2AATMMC4RTAAR1MAPT | |
| SCHEMBL1008700 | 0.74 | PPARA (0.44) | KMT2ANPC1 | |
| SCHEMBL27733436 | 0.74 | KMT2A (0.77) | KMT2AATMMC4RSMN1; SMN2 | |
| SCHEMBL17592780 | 0.73 | HDAC3 (0.59) | KMT2ATAAR1L3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL3324186 | 0.72 | NPC1 (0.66) | KMT2AATMTAAR1MAPTL3MBTL1 | |
| SCHEMBL7843769 | 0.71 | GFER (0.63) | KMT2AMAPTMEN1POLBHPGD | |
| SCHEMBL6807560 | 0.70 | HPGD (0.48) | L3MBTL1HPGD | |
| SCHEMBL27753872 | 0.70 | PPARG (0.45) | KMT2ATAAR1L3MBTL1MEN1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1661890-B1 | PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KOWA CO (JP) | 2011-01-05 | — | — | EP | disclosed |
| EP-1661890-B1 | PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KOWA CO (JP) | 2011-01-05 | — | — | EP | disclosed |
| CN-100425594-C | PPAR activating compound and pharmaceutical composition containing the same | KOWA CO (JP) | 2008-10-15 | — | — | CN | disclosed |
| US-7183295-B2 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183295-B2 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183295-B2 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
| CN-1845905-A | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO (JP) | 2006-10-11 | — | — | CN | disclosed |
| US-7109226-B2 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20060189667-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1661890-A1 | PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Kowa Co., Ltd. (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20050101636-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | KOWA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189667-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | PPARA, PPARG, PPARD | KMT2A 1647/4885ATM 2109/4885MC4R 188/4885 |
| US-20050101636-A1 | PPAR-activating compound and pharmaceutical composition comprising the compound | PPARG, PPARA, PPARD | KMT2A 1522/4885ATM 1895/4885MC4R 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.